New ‘ImmunoPET’ Scan Catches Hidden Multiple Myeloma Standard Tests Miss
A targeted imaging technique can uncover hidden pockets of multiple myeloma that standard hospital scans frequently miss, according to a clinical study published in the journal Radiology.
Researchers at Sylvester Comprehensive Cancer Center, working alongside collaborators at Hoag Cancer Center, found that an antibody-based imaging tool called immunoPET successfully identified active disease in patients whose routine glucose scans came back clear.
Multiple myeloma, a blood cancer that develops inside bone marrow, affects more than 36,000 people in the United States every year. Tracking whether treatments work typically relies on standard PET/CT scans, which look for high glucose consumption in rapidly growing tumor cells. Yet in up to 40% of myeloma cases, cancer cells burn glucose at the exact same rate as surrounding healthy tissue, allowing residual disease to go unnoticed.
“Myeloma cells frequently consume the same amount of glucose as the surrounding normal cells,” said Dr. C. Ola Landgren, chief of the Myeloma Division, director of the Sylvester Myeloma Institute, and senior author of the study. “It’s very well known among radiologists and myeloma experts that some patients who have myeloma in their bones may not light up on PET scans. The methods are simply not designed to reliably capture multiple myeloma.”
To close that gap, researchers designed an antibody tracer that locks directly onto CD38, a specific protein sitting on the surface of myeloma cells.
In a multicenter phase 2 clinical trial involving 60 patients, participants received both conventional glucose scans and the new immunoPET scans. More than 10% of the enrolled patients showed clear signs of active cancer solely on the immunoPET imaging, with follow-up biopsies confirming the presence of live disease.
Hospital Hallway. Source: Unsplash
Overall, immunoPET detected tumors that standard PET/CT missed in 17 patients, or 28% of the trial group.
In one instance, a patient with chronic back pain had normal blood work and clean standard scans, but the antibody scan revealed spinal lesions. Once the patient changed therapies, the pain disappeared. In another case, a patient whose routine workup showed zero evidence of cancer turned out to have nearly 100 myeloma sites spread across the body once scanned with immunoPET.
“Their standard tests showed no evidence of disease, but we found nearly 100 sites of myeloma throughout the body,” Landgren said. “These are exactly the kinds of patients who benefit from better scans.”
The technology did not catch everything, however. Standard scans found tumors that immunoPET missed in 13 patients, or 22% of the cohort, while both imaging tools performed identically in the remaining patients.
Because neither scan caught every tumor alone, researchers emphasized that immunoPET is meant to supplement existing diagnostic tools, including blood work and bone marrow biopsies, rather than discard them.
“If we are going to cure multiple myeloma, we need two things. One, we need really effective medicines. Second, we need to be able to make sure there is no disease left behind after these treatments,” Landgren said. “We are developing new and better technology designed to see where the disease is and make sure we are not missing it.”
Practical hurdles remain before the scan sees widespread clinical adoption. Under the current protocol, the tracer antibody takes a full week to circulate through the bloodstream and bind to cancer cells, complicating scheduling and administration.
Landgren and his team are now developing next-generation scans using smaller antibody fragments. Those changes aim to speed delivery directly to tumors and potentially cut the process down to a single-day outpatient test.
“We show that you can successfully find much more disease,” Landgren said. “It’s a more sensitive and more precise technology, and we have very strong proof of principle that it works and that it’s meaningful.”